The yervoy market size has grown rapidly in recent years. It will grow from $6.01 million in 2025 to $6.66 million in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to approval for melanoma and solid tumors, success of ctla-4 inhibition, oncology center adoption, unmet needs in advanced cancers, improved survival outcomes.
The yervoy market size is expected to see rapid growth in the next few years. It will grow to $9.93 million in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of immunotherapy pipelines, growth of combination regimens, increasing cancer prevalence, rising oncology investments, improved immune profiling. Major trends in the forecast period include growth of immune checkpoint inhibitors, expansion of combination immunotherapy, rising use in advanced oncology, hospital based immuno oncology care, focus on long term cancer survival.
The rising incidence of melanoma is expected to drive the growth of the Yervoy market in the coming years. Melanoma is a type of skin cancer that develops in melanocytes, the cells responsible for producing melanin, which gives skin its color. The increase in melanoma cases is attributed to greater sun exposure, lifestyle changes, and UV radiation resulting from ozone depletion. Enhanced awareness and improved diagnostic techniques have also contributed to more cases being detected. Yervoy, by targeting the CTLA-4 protein to enhance the immune system’s ability to recognize and attack cancer cells, has shown significant benefits for melanoma patients, offering improved survival rates and durable responses even in advanced stages. For example, in January 2024, the American Cancer Society reported that approximately 100,640 new melanoma cases are expected in the United States in 2024, with 59,170 cases in men and 41,470 in women. The organization also estimates that 8,290 people will die from melanoma in 2024, including 5,430 men and 2,860 women. Consequently, the rising incidence of melanoma is supporting growth in the Yervoy market.
Leading companies in the Yervoy market are focusing on developing innovative combination therapies, such as pairing Opdivo (nivolumab) with Yervoy (ipilimumab), to improve treatment efficacy and expand indications across various cancers. This combination works synergistically by targeting complementary immune checkpoint pathways, enhancing the immune response and effectiveness in cancers such as melanoma and renal cell carcinoma. For example, in June 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced promising results from the CheckMate-9DW trial, which evaluated the combination of Opdivo and Yervoy as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The trial showed that the dual immunotherapy regimen significantly improved overall survival compared to standard treatments with lenvatinib or sorafenib, demonstrating statistically significant benefits for patients with advanced HCC.
In September 2024, Ono Pharmaceutical, a Japan-based company, partnered with Bristol-Myers Squibb KK (BMS KK) to expand the use of Opdivo and Yervoy in treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. This collaboration aims to strengthen Ono’s immuno-oncology portfolio and address unmet medical needs in cancer treatment. Bristol-Myers Squibb is a Japan-based company that manufactures and markets Yervoy.
Major companies operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., Ono Pharmaceutical.
North America was the largest region in the yervoy market in 2025. The regions covered in the yervoy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yervoy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the yervoy market by increasing costs related to biologic drug production and cold chain logistics. These impacts are felt most strongly in oncology hospitals across north america, europe, and asia pacific. Higher import duties have added pressure to immunotherapy pricing structures. Distribution efficiency has also been affected by customs compliance requirements. At the same time, tariffs are supporting domestic biologics manufacturing and strengthening regional oncology supply chains.
The yervoy market research report is one of a series of new reports that provides yervoy market statistics, including yervoy industry global market size, regional shares, competitors with a yervoy market share, detailed yervoy market segments, market trends and opportunities, and any further data you may need to thrive in the yervoy industry. This yervoy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used in the treatment of certain cancers by enhancing the body's immune system to target cancer cells. It functions by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, a protein that normally suppresses the immune response.
The main forms of Yervoy are 40 mg and 10 mg. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab used in immunotherapy, administered to stimulate the immune system by inhibiting CTLA-4, thereby improving the body's ability to attack and destroy cancer cells. It is prescribed for conditions such as metastatic melanoma and other cancers. Its indications include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal cancer (CRC). Yervoy is distributed through hospitals, oncology clinics, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.
The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The yervoy market size is expected to see rapid growth in the next few years. It will grow to $9.93 million in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of immunotherapy pipelines, growth of combination regimens, increasing cancer prevalence, rising oncology investments, improved immune profiling. Major trends in the forecast period include growth of immune checkpoint inhibitors, expansion of combination immunotherapy, rising use in advanced oncology, hospital based immuno oncology care, focus on long term cancer survival.
The rising incidence of melanoma is expected to drive the growth of the Yervoy market in the coming years. Melanoma is a type of skin cancer that develops in melanocytes, the cells responsible for producing melanin, which gives skin its color. The increase in melanoma cases is attributed to greater sun exposure, lifestyle changes, and UV radiation resulting from ozone depletion. Enhanced awareness and improved diagnostic techniques have also contributed to more cases being detected. Yervoy, by targeting the CTLA-4 protein to enhance the immune system’s ability to recognize and attack cancer cells, has shown significant benefits for melanoma patients, offering improved survival rates and durable responses even in advanced stages. For example, in January 2024, the American Cancer Society reported that approximately 100,640 new melanoma cases are expected in the United States in 2024, with 59,170 cases in men and 41,470 in women. The organization also estimates that 8,290 people will die from melanoma in 2024, including 5,430 men and 2,860 women. Consequently, the rising incidence of melanoma is supporting growth in the Yervoy market.
Leading companies in the Yervoy market are focusing on developing innovative combination therapies, such as pairing Opdivo (nivolumab) with Yervoy (ipilimumab), to improve treatment efficacy and expand indications across various cancers. This combination works synergistically by targeting complementary immune checkpoint pathways, enhancing the immune response and effectiveness in cancers such as melanoma and renal cell carcinoma. For example, in June 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced promising results from the CheckMate-9DW trial, which evaluated the combination of Opdivo and Yervoy as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The trial showed that the dual immunotherapy regimen significantly improved overall survival compared to standard treatments with lenvatinib or sorafenib, demonstrating statistically significant benefits for patients with advanced HCC.
In September 2024, Ono Pharmaceutical, a Japan-based company, partnered with Bristol-Myers Squibb KK (BMS KK) to expand the use of Opdivo and Yervoy in treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. This collaboration aims to strengthen Ono’s immuno-oncology portfolio and address unmet medical needs in cancer treatment. Bristol-Myers Squibb is a Japan-based company that manufactures and markets Yervoy.
Major companies operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., Ono Pharmaceutical.
North America was the largest region in the yervoy market in 2025. The regions covered in the yervoy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yervoy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the yervoy market by increasing costs related to biologic drug production and cold chain logistics. These impacts are felt most strongly in oncology hospitals across north america, europe, and asia pacific. Higher import duties have added pressure to immunotherapy pricing structures. Distribution efficiency has also been affected by customs compliance requirements. At the same time, tariffs are supporting domestic biologics manufacturing and strengthening regional oncology supply chains.
The yervoy market research report is one of a series of new reports that provides yervoy market statistics, including yervoy industry global market size, regional shares, competitors with a yervoy market share, detailed yervoy market segments, market trends and opportunities, and any further data you may need to thrive in the yervoy industry. This yervoy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used in the treatment of certain cancers by enhancing the body's immune system to target cancer cells. It functions by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, a protein that normally suppresses the immune response.
The main forms of Yervoy are 40 mg and 10 mg. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab used in immunotherapy, administered to stimulate the immune system by inhibiting CTLA-4, thereby improving the body's ability to attack and destroy cancer cells. It is prescribed for conditions such as metastatic melanoma and other cancers. Its indications include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal cancer (CRC). Yervoy is distributed through hospitals, oncology clinics, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.
The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Yervoy Market Characteristics
3. Yervoy Market Supply Chain Analysis
4. Global Yervoy Market Trends and Strategies
5. Yervoy Market Analysis of End Use Industries
7. Global Yervoy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Yervoy Total Addressable Market (TAM) Analysis for the Market
9. Yervoy Market Segmentation
40 ml, 10 ml
10. Yervoy Market Regional and Country Analysis
11. Asia-Pacific Yervoy Market
12. China Yervoy Market
13. India Yervoy Market
14. Japan Yervoy Market
15. Australia Yervoy Market
16. South Korea Yervoy Market
17. Western Europe Yervoy Market
18. UK Yervoy Market
19. Germany Yervoy Market
20. France Yervoy Market
21. Eastern Europe Yervoy Market
22. North America Yervoy Market
23. USA Yervoy Market
24. Canada Yervoy Market
25. South America Yervoy Market
26. Middle East Yervoy Market
27. Africa Yervoy Market
29. Yervoy Market Competitive Landscape and Company Profiles
32. Yervoy Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Yervoy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses yervoy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for yervoy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The yervoy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: 40 ml; 10 ml2) By Clinical Indication: Melanoma; Non-Small Cell Lung Cancer (NSCLC); Renal Cell Carcinoma (RCC); Colorectal Cancer (CRC)
3) By Distribution Channel: Hospitals; Oncology Clinics; Retail Pharmacies; Online Pharmacies
4) By End User: Adult; Geriatric
Companies Mentioned: Bristol-Myers Squibb; Merck & Co.; Ono Pharmaceutical
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Yervoy market report include:- Bristol-Myers Squibb
- Merck & Co.
- Ono Pharmaceutical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.66 Million |
| Forecasted Market Value ( USD | $ 9.93 Million |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 4 |
